Research Topics
| Marco FloridiaSummaryAffiliation: Istituto Superiore di Sanit Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Pregnancy outcomes and antiretroviral treatment in a national cohort of pregnant women with HIV: overall rates and differences according to nationalityM Floridia
Department of Drug Research and Evaluation, Istituto Superiore di Sanita, Rome, Italy
BJOG 114:896-900. 2007..Specific interventions, however, are needed to increase the rates of counselling and HIV testing before pregnancy in foreign women...
Antiretroviral therapy at conception in pregnant women with HIV in Italy: wide range of variability and frequent exposure to contraindicated drugsMarco Floridia
Istituto Superiore di Sanita, Rome, Italy
Antivir Ther 11:941-6. 2006..Therapeutic changes during pregnancy were also analysed...
Lipid profile during pregnancy in HIV-infected womenM Floridia
Department of Drug Research and Evaluation, Istituto Superiore di Sanita, Rome
HIV Clin Trials 7:184-93. 2006..We investigated the evolution of serum lipid levels in HIV-infected pregnant women and the potential effect of antiretroviral treatment during pregnancy using data from a national surveillance study...
Voluntary pregnancy termination among women with HIV in the HAART era (2002-2008): a case series from a national studyMarco Floridia
Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy
AIDS Care 22:50-3. 2010..Women with low CD4 counts and those with an HIV-infected partner represent two groups that should receive particular attention in preventive strategies...
Diagnosis of HIV infection in pregnancy: data from a national cohort of pregnant women with HIV in ItalyM Floridia
Istituto Superiore di Sanità ISS, Department of Drug Evaluation and Research, Rome, Italy
Epidemiol Infect 134:1120-7. 2006..This suggests a good HIV detection during pregnancy, but also the need to reinforce HIV testing strategies among women of childbearing age. We identified some determinants which may be considered for intervention measures...
Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<5M Floridia
Istituto Superiore di Sanita, Rome, Italy
HIV Med 5:1-10. 2004....
Declining HCV seroprevalence in pregnant women with HIVM Floridia
Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy
Epidemiol Infect 138:1317-21. 2010..03-0.29]. Previous IDU was the stronger determinant of HCV co-infection in pregnant women with HIV (aOR 30.9, 95% CI 18.8-51.1). The observed trend is expected to translate into a reduced number of cases of vertical HCV transmission...
Treatment change in pregnancy is a significant risk factor for detectable HIV-1 RNA in plasma at end of pregnancyMarco Floridia
Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy
HIV Clin Trials 11:303-11. 2010..To investigate the risk factors for an HIV-1 RNA plasma viral load above 400 copies/mL in the third trimester of pregnancy...
Plasma lipid profile in pregnant women with HIV receiving nevirapineMarco Floridia
Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161 Rome, Italy
AIDS Patient Care STDS 23:147-52. 2009..Further studies should assess whether this effect is due to an intrinsic activity of nevirapine and define the potential mechanisms involved...
HIV RNA viral load and CD4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancyEnrica Tamburrini
Department of Infectious Diseases, Catholic University, Rome, Italy
Antivir Ther 13:519-27. 2008..In pregnant women taking antiretroviral treatment at conception treatment may be transiently stopped for safety concerns. Limited data are available on the consequences of such discontinuations...
Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomesSilvia Baroncelli
Department of Drug Research and Evaluation, Istituto Superiore di Sanità ISS, Rome, Italy
AIDS Patient Care STDS 23:513-20. 2009..Constant improvements in the rates of HIV suppression were observed, probably driven by the adoption of stronger and more effective regimens and by the increasing options available for combination treatment...
Pregnancy outcomes in women with advanced HIV infection in ItalySilvia Baroncelli
Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy
AIDS Patient Care STDS 25:639-45. 2011..During postpartum care, women with more advanced HIV infection should receive particular care to prevent loss of virologic suppression...
Effect of HCV infection on glucose metabolism in pregnant women with HIV receiving HAARTCarmela Pinnetti
Department of Infectious Diseases, Catholic University, Rome, Italy
HIV Clin Trials 10:403-12. 2009..A prospective study was designed to evaluate the prevalence and determinants of glucose metabolism abnormalities (GMAs) among HIV-1-infected pregnant women receiving highly active antiretroviral therapy (HAART)...
Lipodystrophy is an independent predictor of hypertriglyceridemia during pregnancy in HIV-infected womenMarco Floridia
Department of Drug Research and Evaluation, Istituto Superiore di Sanit, Rome
AIDS 20:944-7. 2006..Protease inhibitor treatment was also independently associated with hypertriglyceridemia...
Common occurrence of anaemia at the end of pregnancy following exposure to zidovudine-free regimensCarmela Pinnetti
Department of Infectious Diseases, Catholic University, Rome, Italy
J Infect 63:144-50. 2011..Although zidovudine-free regimens are increasingly used in pregnancy, their haematological effects in mothers and newborns are incompletely defined...
Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimensSilvia Baroncelli
Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Viale Regina Elena 299, Rome, Italy
Ther Drug Monit 30:604-10. 2008..Subtherapeutic predose concentrations among HIV-infected pregnant women were more commonly found with NVP than with protease inhibitors. LPV administration was associated with the best viral load suppression...
Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced diseaseAntonella Esposito
Dpt, of Clinical Medicine, Sapienza University of Rome, Rome, Italy
BMC Infect Dis 11:341. 2011..The optimal therapeutic strategies for patients presenting with advanced disease at HIV-1 diagnosis are as yet incompletely defined...
Factors influencing gestational age-adjusted birthweight in a national series of 600 newborns from mothers with HIVMarco Floridia
Department of Drug Research and Evaluation, Istituto Superiore di Sanità ISS, Rome, Italy
HIV Clin Trials 9:287-97. 2008..Few studies have assessed the determinants of birthweight in newborns from HIV-positive mothers in analyses that adjusted for different gestational age at delivery...
Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfectionLiliana Elena Weimer
Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy
J Antimicrob Chemother 68:193-9. 2013....
A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infectionS Vella
Laboratory of Virology, Istituto Superiore di Sanita, Rome, Italy
Antivir Ther 1:129-40. 1996..The combination of drugs with different mechanisms of action represents an advance in the treatment of HIV infection...
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministrationSilvia Baroncelli
Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy
Ann Pharmacother 44:838-43. 2010..The safety and efficacy of both drugs have been investigated, but there is no information on possible pharmacokinetic interactions between these 2 drugs in clinical practice...
Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapySilvia Baroncelli
Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Rome, Italy
J Antimicrob Chemother 67:1479-85. 2012..To evaluate the evolution of HIV-1 coreceptor tropism in proviral DNA of patients during maraviroc-based therapy...
Hematological effects of zidovudine prophylaxis in newborn infants with and without prenatal exposure to zidovudineSilvia Baroncelli
Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità ISS, Rome, Italy
J Med Virol 83:551-6. 2011..The distinct effects of these two pathways should be considered...
Quality of life outcomes of combination zidovudine- didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patientsR Bucciardini
Laboratory of Virology, Istituto Superiore di Sanita, Rome, Italy
AIDS 14:2567-74. 2000....
Health-related quality of life outcomes in HIV-infected patients starting different combination regimens in a randomized multinational trial: the INITIO-QoL substudyRaffaella Bucciardini
Department of Drug Research and Evaluation, Istituto Superiore di Sanita, Rome, Italy
AIDS Res Hum Retroviruses 23:1215-22. 2007....
Gender differences in the treatment of HIV infectionMarco Floridia
Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161 Rome, Italy
Pharmacol Res 58:173-82. 2008..To obtain this goal, specific studies should be designed and females' participation in both cohort studies and clinical trials should be promoted...
HIV-related morbidity and mortality in patients starting protease inhibitors in very advanced HIV disease (CD4 count of < 50 cells/microL): an analysis of 338 clinical events from a randomized clinical trialM Floridia
ISS-IP 1 Study Group, Laboratory of Virology, Istituto Superiore di Sanit, Rome, Italy
HIV Med 3:75-84. 2002..This threshold can therefore be considered a clinically effective goal of treatment with respect to occurrence of all AIDS defining conditions in patients starting PIs in very advanced HIV disease...
Pregnancy and HIV infection: A european consensus on managementOriol Coll
Hospital Clinic, University of Barcelona, Spain
AIDS 16:S1-18. 2002
Epidemiological and clinical features of pregnant women with HIV: a 21-year perspective from a highly specialized regional center in southern ItalyPasquale Martinelli
Department of Gynecology and Obstetrics, Centre for STD and HIV AIDS in Obstetrics and Gynecology, University of Naples Federico II, Napoli, Italy
HIV Clin Trials 9:36-42. 2008..To analyze the changes over two decades in HIV-infected pregnant women followed at a highly specialized regional center for antenatal care in southern Italy...
Efficacy of highly active antiretroviral therapy in HIV-infected, institutionalized orphaned children in TanzaniaClaudio Blè
Department of Infectious Diseases, S M Annunziata Hospital, ASL, Florence, Italy
Acta Paediatr 96:1090-4. 2007
